Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New neuromuscular blocking drugs

J M Hunter1

  • 1University Department of Anaesthesia, Royal Liverpool University Hospital, United Kingdom.

The New England Journal of Medicine
|June 22, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuromuscular blocking drugs in the critically ill.

BJA education·2021
Same author

Reversal of neuromuscular block.

BJA education·2021
Same author

The many contributions of WW Mapleson to the British Journal of Anaesthesia.

British journal of anaesthesia·2019
Same author

Tracheal intubation without the use of neuromuscular blocking drugs. Reply to Br J Anaesth 2018; 121: e9-10.

British journal of anaesthesia·2018
Same author

Should neuromuscular blocking agents always be used for tracheal intubation? Reply to Br J Anaesth 2018; 122: e8-9.

British journal of anaesthesia·2018
Same author

Dr J. Edmund Riding CBE, MD, FRCA, FRCS (Hon), FCARCSI (Hon), FANZCA (Hon): 1924-2018.

British journal of anaesthesia·2018

New nondepolarizing neuromuscular blocking drugs offer advantages over succinylcholine. Rocuronium and mivacurium show promise for specific clinical scenarios, though an ideal drug remains elusive.

Area of Science:

  • Anesthesiology
  • Pharmacology

Background:

  • Nondepolarizing neuromuscular blocking drugs are crucial in anesthesia.
  • Succinylcholine is a common depolarizing agent, but has limitations.
  • Newer agents offer potential improvements in safety and efficacy.

Purpose of the Study:

  • To compare the clinical utility of new nondepolarizing neuromuscular blocking drugs.
  • To identify advantages and limitations of rocuronium, mivacurium, pipecuronium, and doxacurium.
  • To define the characteristics of an ideal neuromuscular blocking agent.

Main Methods:

  • Review of clinical pharmacology and efficacy data for new neuromuscular blocking drugs.
  • Comparison of onset and duration of action, recovery profiles, and cardiovascular effects.
  • Assessment of suitability for specific patient populations and procedural durations.

Related Experiment Videos

Main Results:

  • Rocuronium offers rapid onset, similar to succinylcholine, useful for patients with residual gastric contents.
  • Mivacurium provides faster recovery than atracurium when plasma cholinesterase is normal, suitable for short procedures.
  • Pipecuronium and doxacurium have minimal cardiovascular effects but limited clinical utility due to long, variable action.

Conclusions:

  • Rocuronium may replace vecuronium due to similar profiles and faster onset.
  • Mivacurium is beneficial for short procedures requiring rapid reversal.
  • An ideal nondepolarizing neuromuscular blocker with rapid onset, moderate duration, and organ-independent clearance is still needed.